Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7M, up 45% YoY for LIVMARLI and 28% for Bile Acid Medicines. The company received FDA approval for ATEBRIOZ and reported positive Phase 3 results for LIVMARLI, ATEBRIOZ, and brelovitug. Mirum raised full-year net product sales guidance and expects multiple regulatory submissions in 2027. Total revenue was $133.0M, with operating expenses at $130.4M.
How this was made
The 30-second read
Why it matters
The combination of earnings beat, new product launch, and strong pipeline data provides a multi‑factor catalyst likely to move the stock.
Market read
First‑report of FDA approval and trial success makes this a high‑impact earnings story for biotech investors.
What to watch
Potential reimbursement challenges for ATEBRIOZ and brelovitug could temper upside.
Background
Mirum Pharmaceuticals released its Q3 2026 financial results, announced FDA approval of ATEBRIOZ, and disclosed positive Phase 3 data for its liver disease portfolio.
Ticker impact
Mirum reported Q3 2026 results, FDA approval of ATEBRIOZ and positive Phase 3 data for LIVMARLI and brelovitug, providing fresh material for the stock.
upside pressure as market prices in FDA approval and strong sales growth
First disclosure of FDA approval and robust sales figures creates immediate upside bias.
Market effects
Boosts sentiment for rare‑disease biotech sector and may lift peers with similar pipelines.
Positive for US biotech listings, especially Nasdaq‑listed rare‑disease firms.
Highlights continued FDA activity supporting global biotech investment themes.
Counterpoint
If the market has already priced in the approval, any post‑earnings guidance miss could trigger a pullback.
Key entities
- CompanyMirum Pharmaceuticals
US‑listed biotech focused on rare liver diseases.
- ExecutiveChris Peetz
CEO of Mirum, quoted on the company's progress.
